Brelovitug

Phase 3Small molecule

MMirum Pharmaceuticals, Inc.

Brelovitug is one of 3 small molecule programs targeting Chronic Hepatitis D. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Hepatitis DRecruiting

Chronic Hepatitis D InfectionActive, not recruiting

Chronic Hepatitis DPreclinical

Recruiting

Chronic Hepatitis D InfectionPhase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Chronic Hepatitis D

#DrugCompanyPhaseTrials

Brelovitug

MMirum Pharmaceuticals, Inc.

Phase 3

1 2

HEPCLUDEX

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Active, not recruiting

Chronic Hepatitis D Infection

NCT07298330

PreclinicalRecruiting

Chronic Hepatitis D

NCT07454837

Q3 2029

PreclinicalActive, not recruiting

Chronic Hepatitis D Infection

NCT06907290

Phase 3Recruiting

Chronic Hepatitis D Infection

NCT07200908

Clinical

Trials by Indication[1]

Chronic Hepatitis D Infection3 trials

A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)

Active, not recruiting·MMirum Pharmaceuticals, Inc.·Preclinical·NCT06907290·150 enrolled

A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Recruiting·MMirum Pharmaceuticals, Inc.·Phase 3·NCT07200908·172 enrolled

A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

Active, not recruiting·MMirum Pharmaceuticals, Inc.·Phase 3·NCT07298330·80 enrolled

Chronic Hepatitis D1 trial

A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)

Recruiting·MMirum Pharmaceuticals, Inc.·Preclinical·NCT07454837·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Brelovitug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Brelovitug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Brelovitug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mirum Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMirum Pharmaceuticals, Inc.

Brelovitug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q3 2029

Trials by Indication[1]

Chronic Hepatitis D Infection3 trials

Chronic Hepatitis D1 trial

References

Drug Info

Quick Facts

Related News